Home / Market News / $TWST
benzinga Corporate Catalyst Impact 75/100 ● positive

Twist Bioscience shares are trading higher after Leerink Partners maintained an Outperform rating on the stock and raised its price target from $160 to $190.

Sep 29, 2026, 7:03 PM UTC · Primary ticker $TWST

This headline indicates a positive sentiment shift for Twist Bioscience, driven by analyst endorsement. The raised price target suggests increased confidence in the company's future performance, likely leading to continued upward pressure on its stock price. This could also signal broader investor interest in the biotechnology tools sector.

The maintained 'Outperform' rating and significant price target increase from a reputable firm like Leerink Partners serve as a strong positive catalyst for Twist Bioscience. This analyst action signals a belief in the company's strong fundamentals, growth prospects, or recent positive developments, which can attract new investors and encourage existing holders. The primary impact is on TWST, but it could also generate positive sentiment for the broader biotechnology tools sector, as it highlights investor interest in innovative life science technologies. Key risks include the possibility of the analyst's projections not materializing or broader market downturns overshadowing company-specific news. Trading implications suggest potential for continued short-term upside for TWST.

$TWST positive Analyst upgrade and price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.